SCHEMBL1849690

SCHEMBL1849690

CCOC(=O)c1cc(F)cc(-c2ccc(F)c3cc(Cc4cc(F)cc(Cl)c4)sc23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 3/20 0.49
MAPT P10636 5/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CDC7 O00311 2/20 0.35
DBF4 Q9UBU7 2/20 0.35
PDK2 Q15119 1/20 0.34
XPO1 O14980 1/20 0.33
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
RECQL P46063 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1859911 0.96 GPR52 (0.46) GPR52MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1847924 0.92 GPR52 (0.56) GPR52MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1851979 0.89 GPR52 (0.53) GPR52MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1848327 0.88 GPR52 (0.44) GPR52MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1859640 0.87 GPR52 (0.47) GPR52MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1851422 0.86 GPR52 (0.49) GPR52
SCHEMBL3219607 0.86 GPR52 (0.63) GPR52MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1851960 0.85 GPR52 (0.55) GPR52MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1851614 0.85 GPR52 (0.38) GPR52MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL1856025 0.85 GPR52 (0.41) GPR52MAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885MAPT 4174/4885NPC1 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.